Literature DB >> 21922031

Glitazones for human nonalcoholic steatohepatitis.

Raluca Pais1, Ioana Moraru, Vlad Ratziu.   

Abstract

The rationale for specific pharmacologic therapy in nonalcoholic steatohepatitis (NASH) is determined by the potential for disease progression and the difficulties, in many patients, of successfully implementing diet and lifestyle changes over the long term. Owing to their ability to correct insulin resistance, insulin-sensitizing agents are attractive candidates for the treatment of NASH. In this review we provide an insight into the mechanism of action, therapeutic efficacy and safety issues regarding the use of glitazones in NASH.

Entities:  

Keywords:  fibrosis; glitazones; insulin resistance; insulin sensitizing drugs; nonalcoholic steatohepatitis; steatosis

Year:  2011        PMID： 21922031      PMCID： PMC3165207          DOI： 10.1177/1756283X11409793

Source DB:  PubMed          Journal:  Therap Adv Gastroenterol        ISSN： 1756-283X            Impact factor:   4.409


  52 in total

1.  Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement.

Authors:  Glen Lutchman; Kittichai Promrat; David E Kleiner; Theo Heller; Marc G Ghany; Jack A Yanovski; T Jake Liang; Jay H Hoofnagle
Journal:  Clin Gastroenterol Hepatol       Date:  2006-06-30       Impact factor: 11.382

Review 2.  Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites.

Authors:  Brent A Neuschwander-Tetri
Journal:  Hepatology       Date:  2010-08       Impact factor: 17.425

3.  Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity.

Authors:  Elisabetta Bugianesi; Uberto Pagotto; Rita Manini; Ester Vanni; Amalia Gastaldelli; Rosaria de Iasio; Elena Gentilcore; Stefania Natale; Maurizio Cassader; Mario Rizzetto; Renato Pasquali; Giulio Marchesini
Journal:  J Clin Endocrinol Metab       Date:  2005-03-29       Impact factor: 5.958

4.  The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis.

Authors:  Mustafa S Ascha; Ibrahim A Hanouneh; Rocio Lopez; Tarek Abu-Rajab Tamimi; Ariel F Feldstein; Nizar N Zein
Journal:  Hepatology       Date:  2010-06       Impact factor: 17.425

5.  Hepatic stellate cells and fibrosis progression in patients with nonalcoholic fatty liver disease.

Authors:  Ariel E Feldstein; Bettina G Papouchado; Paul Angulo; Schyler Sanderson; Leon Adams; Gregory J Gores
Journal:  Clin Gastroenterol Hepatol       Date:  2005-04       Impact factor: 11.382

Review 6.  Therapeutic trials in nonalcoholic steatohepatitis: insulin sensitizers and related methodological issues.

Authors:  Vlad Ratziu; Stephen Caldwell; Brent A Neuschwander-Tetri
Journal:  Hepatology       Date:  2010-12       Impact factor: 17.425

7.  Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis.

Authors:  Yoon K Loke; Sonal Singh; Curt D Furberg
Journal:  CMAJ       Date:  2008-12-10       Impact factor: 8.262

8.  Long term prognosis of fatty liver: risk of chronic liver disease and death.

Authors:  S Dam-Larsen; M Franzmann; I B Andersen; P Christoffersen; L B Jensen; T I A Sørensen; U Becker; F Bendtsen
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

9.  Decreased survival of subjects with elevated liver function tests during a 28-year follow-up.

Authors:  Cecilia Söderberg; Per Stål; Johan Askling; Hans Glaumann; Greger Lindberg; Joel Marmur; Rolf Hultcrantz
Journal:  Hepatology       Date:  2010-02       Impact factor: 17.425

Review 10.  Non-alcoholic fatty liver disease pathogenesis: the present and the future.

Authors:  S Petta; C Muratore; A Craxì
Journal:  Dig Liver Dis       Date:  2009-02-14       Impact factor: 4.088
View more
  3 in total

1.  Should visceral fat, strictly linked to hepatic steatosis, be depleted to improve survival?

Authors:  Carmine Finelli; Giovanni Tarantino
Journal:  Hepatol Int       Date:  2012-10-26       Impact factor: 6.047

Review 2.  4Ps medicine of the fatty liver: the research model of predictive, preventive, personalized and participatory medicine-recommendations for facing obesity, fatty liver and fibrosis epidemics.

Authors:  Francesca Maria Trovato; Daniela Catalano; Giuseppe Musumeci; Guglielmo M Trovato
Journal:  EPMA J       Date:  2014-12-07       Impact factor: 6.543

Review 3.  Anti-NASH Drug Development Hitches a Lift on PPAR Agonism.

Authors:  Joost Boeckmans; Alessandra Natale; Matthias Rombaut; Karolien Buyl; Vera Rogiers; Joery De Kock; Tamara Vanhaecke; Robim M Rodrigues
Journal:  Cells       Date:  2019-12-21       Impact factor: 6.600
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.